{"id":946080,"date":"2026-03-22T19:55:04","date_gmt":"2026-03-22T23:55:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/apogee-therapeutics-to-host-conference-call-to-report-part-a-52-week-data-from-the-phase-2-apex-trial-of-zumilokibart-apg777-in-patients-with-moderate-to-severe-atopic-dermatitis-on-march-23-2026\/"},"modified":"2026-03-22T19:55:04","modified_gmt":"2026-03-22T23:55:04","slug":"apogee-therapeutics-to-host-conference-call-to-report-part-a-52-week-data-from-the-phase-2-apex-trial-of-zumilokibart-apg777-in-patients-with-moderate-to-severe-atopic-dermatitis-on-march-23-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/apogee-therapeutics-to-host-conference-call-to-report-part-a-52-week-data-from-the-phase-2-apex-trial-of-zumilokibart-apg777-in-patients-with-moderate-to-severe-atopic-dermatitis-on-march-23-2026\/","title":{"rendered":"Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026"},"content":{"rendered":"

\nWebcast to be held Monday, March 23rd at 8:00 a.m. ET
\n<\/h2>\n
\n

SAN FRANCISCO and BOSTON, March 22, 2026 (GLOBE NEWSWIRE) — Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced it will report Part A 52-week data from the Phase 2 APEX trial of zumilokibart on Monday, March 23, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET to discuss the results.<\/p>\n

\n Webcast Details<\/strong>
\n
Apogee Therapeutics\u2019 live webcast of the Phase 2 APEX Part A results will begin on Monday, March 23rd<\/sup> at 8:00 a.m. ET. The live webcast can be accessed via this\u00a0link<\/a> or the Investors section on the Company\u2019s website at https:\/\/investors.apogeetherapeutics.com\/news-events\/events<\/a>. A replay of the webcast will be available following the call.<\/p>\n

\n About Apogee
<\/strong>Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment of AD, asthma, EoE, Chronic Obstructive Pulmonary Disease (COPD) and other I&I indications. Apogee\u2019s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Zumilokibart, the company\u2019s most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets, as well as asthma and EoE. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class efficacy and dosing through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today\u2019s standard of care. For more information, please visit https:\/\/apogeetherapeutics.com<\/a>.<\/p>\n

\n Investor Contact:<\/strong>
\n
Noel Kurdi
VP, Investor Relations
Apogee Therapeutics, Inc.
Noel.Kurdi@apogeetherapeutics.com<\/a><\/p>\n

\n Media Contact:<\/strong>
\n
Dan Budwick
1AB Media
dan@1abmedia.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Webcast to be held Monday, March 23rd at 8:00 a.m. ET SAN FRANCISCO and BOSTON, March 22, 2026 (GLOBE NEWSWIRE) — Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced it will report Part A 52-week data from the Phase 2 APEX trial of zumilokibart on Monday, March 23, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. Webcast Details Apogee Therapeutics\u2019 live webcast of the Phase 2 APEX Part A results will begin on Monday, March 23rd at 8:00 a.m. ET. The live webcast can be accessed via … <\/p>\n

Continue reading “Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-946080","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nApogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/apogee-therapeutics-to-host-conference-call-to-report-part-a-52-week-data-from-the-phase-2-apex-trial-of-zumilokibart-apg777-in-patients-with-moderate-to-severe-atopic-dermatitis-on-march-23-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Webcast to be held Monday, March 23rd at 8:00 a.m. ET SAN FRANCISCO and BOSTON, March 22, 2026 (GLOBE NEWSWIRE) — Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced it will report Part A 52-week data from the Phase 2 APEX trial of zumilokibart on Monday, March 23, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. Webcast Details Apogee Therapeutics\u2019 live webcast of the Phase 2 APEX Part A results will begin on Monday, March 23rd at 8:00 a.m. ET. The live webcast can be accessed via … Continue reading "Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/apogee-therapeutics-to-host-conference-call-to-report-part-a-52-week-data-from-the-phase-2-apex-trial-of-zumilokibart-apg777-in-patients-with-moderate-to-severe-atopic-dermatitis-on-march-23-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-22T23:55:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NjQ2MiM3NDk3ODUyIzIyNTkyMjc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apogee-therapeutics-to-host-conference-call-to-report-part-a-52-week-data-from-the-phase-2-apex-trial-of-zumilokibart-apg777-in-patients-with-moderate-to-severe-atopic-dermatitis-on-march-23-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apogee-therapeutics-to-host-conference-call-to-report-part-a-52-week-data-from-the-phase-2-apex-trial-of-zumilokibart-apg777-in-patients-with-moderate-to-severe-atopic-dermatitis-on-march-23-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026\",\"datePublished\":\"2026-03-22T23:55:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apogee-therapeutics-to-host-conference-call-to-report-part-a-52-week-data-from-the-phase-2-apex-trial-of-zumilokibart-apg777-in-patients-with-moderate-to-severe-atopic-dermatitis-on-march-23-2026\\\/\"},\"wordCount\":364,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apogee-therapeutics-to-host-conference-call-to-report-part-a-52-week-data-from-the-phase-2-apex-trial-of-zumilokibart-apg777-in-patients-with-moderate-to-severe-atopic-dermatitis-on-march-23-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3NjQ2MiM3NDk3ODUyIzIyNTkyMjc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apogee-therapeutics-to-host-conference-call-to-report-part-a-52-week-data-from-the-phase-2-apex-trial-of-zumilokibart-apg777-in-patients-with-moderate-to-severe-atopic-dermatitis-on-march-23-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apogee-therapeutics-to-host-conference-call-to-report-part-a-52-week-data-from-the-phase-2-apex-trial-of-zumilokibart-apg777-in-patients-with-moderate-to-severe-atopic-dermatitis-on-march-23-2026\\\/\",\"name\":\"Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apogee-therapeutics-to-host-conference-call-to-report-part-a-52-week-data-from-the-phase-2-apex-trial-of-zumilokibart-apg777-in-patients-with-moderate-to-severe-atopic-dermatitis-on-march-23-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apogee-therapeutics-to-host-conference-call-to-report-part-a-52-week-data-from-the-phase-2-apex-trial-of-zumilokibart-apg777-in-patients-with-moderate-to-severe-atopic-dermatitis-on-march-23-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3NjQ2MiM3NDk3ODUyIzIyNTkyMjc=\",\"datePublished\":\"2026-03-22T23:55:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apogee-therapeutics-to-host-conference-call-to-report-part-a-52-week-data-from-the-phase-2-apex-trial-of-zumilokibart-apg777-in-patients-with-moderate-to-severe-atopic-dermatitis-on-march-23-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apogee-therapeutics-to-host-conference-call-to-report-part-a-52-week-data-from-the-phase-2-apex-trial-of-zumilokibart-apg777-in-patients-with-moderate-to-severe-atopic-dermatitis-on-march-23-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apogee-therapeutics-to-host-conference-call-to-report-part-a-52-week-data-from-the-phase-2-apex-trial-of-zumilokibart-apg777-in-patients-with-moderate-to-severe-atopic-dermatitis-on-march-23-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3NjQ2MiM3NDk3ODUyIzIyNTkyMjc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3NjQ2MiM3NDk3ODUyIzIyNTkyMjc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apogee-therapeutics-to-host-conference-call-to-report-part-a-52-week-data-from-the-phase-2-apex-trial-of-zumilokibart-apg777-in-patients-with-moderate-to-severe-atopic-dermatitis-on-march-23-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/apogee-therapeutics-to-host-conference-call-to-report-part-a-52-week-data-from-the-phase-2-apex-trial-of-zumilokibart-apg777-in-patients-with-moderate-to-severe-atopic-dermatitis-on-march-23-2026\/","og_locale":"en_US","og_type":"article","og_title":"Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026 - Market Newsdesk","og_description":"Webcast to be held Monday, March 23rd at 8:00 a.m. ET SAN FRANCISCO and BOSTON, March 22, 2026 (GLOBE NEWSWIRE) — Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced it will report Part A 52-week data from the Phase 2 APEX trial of zumilokibart on Monday, March 23, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. Webcast Details Apogee Therapeutics\u2019 live webcast of the Phase 2 APEX Part A results will begin on Monday, March 23rd at 8:00 a.m. ET. The live webcast can be accessed via … Continue reading \"Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/apogee-therapeutics-to-host-conference-call-to-report-part-a-52-week-data-from-the-phase-2-apex-trial-of-zumilokibart-apg777-in-patients-with-moderate-to-severe-atopic-dermatitis-on-march-23-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-22T23:55:04+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NjQ2MiM3NDk3ODUyIzIyNTkyMjc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apogee-therapeutics-to-host-conference-call-to-report-part-a-52-week-data-from-the-phase-2-apex-trial-of-zumilokibart-apg777-in-patients-with-moderate-to-severe-atopic-dermatitis-on-march-23-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apogee-therapeutics-to-host-conference-call-to-report-part-a-52-week-data-from-the-phase-2-apex-trial-of-zumilokibart-apg777-in-patients-with-moderate-to-severe-atopic-dermatitis-on-march-23-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026","datePublished":"2026-03-22T23:55:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apogee-therapeutics-to-host-conference-call-to-report-part-a-52-week-data-from-the-phase-2-apex-trial-of-zumilokibart-apg777-in-patients-with-moderate-to-severe-atopic-dermatitis-on-march-23-2026\/"},"wordCount":364,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apogee-therapeutics-to-host-conference-call-to-report-part-a-52-week-data-from-the-phase-2-apex-trial-of-zumilokibart-apg777-in-patients-with-moderate-to-severe-atopic-dermatitis-on-march-23-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NjQ2MiM3NDk3ODUyIzIyNTkyMjc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apogee-therapeutics-to-host-conference-call-to-report-part-a-52-week-data-from-the-phase-2-apex-trial-of-zumilokibart-apg777-in-patients-with-moderate-to-severe-atopic-dermatitis-on-march-23-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/apogee-therapeutics-to-host-conference-call-to-report-part-a-52-week-data-from-the-phase-2-apex-trial-of-zumilokibart-apg777-in-patients-with-moderate-to-severe-atopic-dermatitis-on-march-23-2026\/","name":"Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apogee-therapeutics-to-host-conference-call-to-report-part-a-52-week-data-from-the-phase-2-apex-trial-of-zumilokibart-apg777-in-patients-with-moderate-to-severe-atopic-dermatitis-on-march-23-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apogee-therapeutics-to-host-conference-call-to-report-part-a-52-week-data-from-the-phase-2-apex-trial-of-zumilokibart-apg777-in-patients-with-moderate-to-severe-atopic-dermatitis-on-march-23-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NjQ2MiM3NDk3ODUyIzIyNTkyMjc=","datePublished":"2026-03-22T23:55:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apogee-therapeutics-to-host-conference-call-to-report-part-a-52-week-data-from-the-phase-2-apex-trial-of-zumilokibart-apg777-in-patients-with-moderate-to-severe-atopic-dermatitis-on-march-23-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/apogee-therapeutics-to-host-conference-call-to-report-part-a-52-week-data-from-the-phase-2-apex-trial-of-zumilokibart-apg777-in-patients-with-moderate-to-severe-atopic-dermatitis-on-march-23-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apogee-therapeutics-to-host-conference-call-to-report-part-a-52-week-data-from-the-phase-2-apex-trial-of-zumilokibart-apg777-in-patients-with-moderate-to-severe-atopic-dermatitis-on-march-23-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NjQ2MiM3NDk3ODUyIzIyNTkyMjc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NjQ2MiM3NDk3ODUyIzIyNTkyMjc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apogee-therapeutics-to-host-conference-call-to-report-part-a-52-week-data-from-the-phase-2-apex-trial-of-zumilokibart-apg777-in-patients-with-moderate-to-severe-atopic-dermatitis-on-march-23-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/946080","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=946080"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/946080\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=946080"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=946080"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=946080"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}